Please assess the completion status of the following clinical trial:

Trial Title: MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 years or greater~* Cytologic / histologic diagnosis ovarian cancer~* Stage of disease at diagnosis IC -IV~* Performance status (ECOG) \< 3~* Indication for chemotherapy treatment~* Written informed consent~Exclusion Criteria:~* Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are being adequately treated)~* Cerebral metastases~* Neutrophils \< 1000/mm3, platelets \< 100000/mm3, hemoglobin \< 8g/dl~* Creatinine \> o = 1.25 times the upper normal limit~* GOT or GPT \> o = 1.25 times the upper normal limit, except in case of liver metastases)~* Patient's inability to comply with followup

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SINGLE ARM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).